Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VITAL: Aflibercept + Docetaxel in 2nd Line NSCLC
NCT00532155Phase 3Completed
- Sponsor
- Sanofi
- Start
- Sep 2007
- Primary completion
- Jan 2011
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 32
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Aflibercept/Docetaxel with Placebo/Docetaxel (2 arms). Primary endpoint: Overall Survival. Started Sep 2007; status: completed.
02
Drugs
aflibercept
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00532155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00532155.